Novartis: 4Q Sales Figures

Novartis reported fourth-quarter results yesterday. Its sales grew by 10 percent to $14.2 billion.

Novartis, the first European drugmaker, yesterday released its 4Q results. Pharma sales rose 3% for the quarter to $8.0 billion, and 7% for the year to $30.6 billion. The Sandoz generics unit was up 10% in 4Q10 to $2.4 billion and 14% for FY10 ($8.5 billion). The integration of Alcon added $1.8 billion to 4Q10 sales and $2.4 billion for FY10. The biggest growth in the pharma segment came from the Oncology group, with sales of $2.7 billion (+9%) in 4Q10 and $10.0 billion (+11%) in FY10, driven by Gleevec and Tasigna sales.

4Q Revenues: $14.2 billion (+10%)

4Q Earnings: $2.3 billion (-2%)

FY Revenues: $50.6 billion (